Triclosan and triclosan-loaded liposomal nanoparticles in the treatment of acute experimental toxoplasmosis

Experimental Parasitology

Volumn 149, Issue , 2015, Pages 54-64

  El Zawawy, Lobna A ^a   El Said, Doaa ^a   Mossallam, Shereen F ^a   Ramadan, Heba S ^b   Younis, Salwa S ^a  

^a ALEXANDRIA UNIVERSITY   (Egypt)

^b Alexandria University Faculty Of Science   (Egypt)

Author keywords

Liposomes; RH HXGPRT( ) virulent strain; Tachyzoites; Toxoplasma gondii; Triclosan

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; LIPOSOME; NANOPARTICLE; TRICLOSAN; ANTIINFECTIVE AGENT; THYROXINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL VACUOLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FATTY ACID SYNTHESIS; LIVER FUNCTION TEST; MACROPHAGE; MOUSE; NONHUMAN; PARASITE LOAD; PARASITE VIRULENCE; PARTICLE SIZE; SCANNING ELECTRON MICROSCOPY; TACHYZOITE; TOXOPLASMA GONDII; TOXOPLASMOSIS; TRANSMISSION ELECTRON MICROSCOPY; ACUTE DISEASE; ANIMAL; ASCITES FLUID; BLOOD; DRUG EFFECTS; LIVER; ORAL DRUG ADMINISTRATION; PARASITOLOGY; PATHOGENICITY; TOXOPLASMA; TOXOPLASMOSIS, ANIMAL; ULTRASTRUCTURE; VIRULENCE;

MURINAE; MUS; TOXOPLASMA GONDII;

ACUTE DISEASE; ADMINISTRATION, ORAL; ALANINE TRANSAMINASE; ANIMALS; ANTI-INFECTIVE AGENTS; ASCITIC FLUID; ASPARTATE AMINOTRANSFERASES; LIPOSOMES; LIVER; MICE; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PARTICLE SIZE; THYROXINE; TOXOPLASMA; TOXOPLASMOSIS, ANIMAL; TRICLOSAN; VIRULENCE;

EID: 84921033998     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2014.12.007     Document Type: Article

References (69)

1. Allmyr M., Panagiotidis G., Sparve E., Diczfalusy U., Sandborgh-Englund G. Human exposure to triclosan via toothpaste does not change CYP3A4 activity or plasma concentrations of thyroid hormones. Basic Clin. Pharmacol. Toxicol 2009, 105(5):339-344.
2. Alving C.R. Liposomes as drug carriers in leishmaniasis and malaria. Parasitol. Today 1986, 2(4):101-107.
3. Araujo F.G., Huskinson J., Remington J.S., Mazumdar J., Masek K., Striepen B., et al. Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii. Antimicrob. Agents Chemother 1991, 35(2):293-299.
4. Araujo F.G., Huskinson-Mark J., Gutteridge W.E., Remington J.S. In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii. Antimicrob. Agents Chemother 1992, 36(2):326-330.
5. Bangham A.D. Development of the liposome concept. Liposomes in Biological Systems 1980, 1-24. John Wiley & Sons, Chichester. G. Gregoridiadis, A.C. Allison (Eds.).
6. Barakat A.M.A. Some diagnostic studies on male New Zealand rabbit experimentally infected with Toxoplasma gondii strain. Global Vet 2007, 1(1):17-23.
7. Bork S., Yokoyama N., Matsuo T., Claveria F.G., Fujisaki K., Igarashi I. Growth inhibitory effect of triclosan on equine and bovine Babesia parasites. Am. J. Trop. Med. Hyg 2003, 68(3):334-340.
8. Burkhardt D., Wiesner J., Stoesser N., Ramharter M., Uhlemann A.C., Issifou S., et al. Delayed parasite elimination in human infections treated with clindamycin parallels 'delayed death' of Plasmodium falciparum in vitro. Int. J. Parasitol 2007, 37(7):777-785.
9. Burns W.A. Thick sections: technique and applications. Diagnostic Electron Microscopy 1978, 141-166. John Wiley & Sons, New York. G.F. Trump, R.J. Jones (Eds.).
10. Cañón-Franco W.A., López-Orozco N., Gómez-Marín J.E., Dubey J.P. An overview of seventy years of research (1944-2014) on toxoplasmosis in Colombia, South America. Parasit. Vectors 2014, 4:7-427.
11. Cauchetier E., Paul M., Rivollet D., Fessi H., Astier A., Deniau M. Therapeutic evaluation of free and liposome-encapsulated atovaquone in the treatment of murine leishmaniasis. Int. J. Parasitol 2000, 30(6):777-783.
12. Chang H.R., Comte R., Pechère J.C. In vitro and in vivo effects of doxycycline on Toxoplasma gondii. Antimicrob. Agents Chemother 1990, 34(5):775-780.
13. Cheng G., Muench S.P., Zhou Y., Afanador G.A., Mui E.J., Fomovska A., et al. Design, synthesis, and biological activity of diaryl ether inhibitors of Toxoplasma gondii enoyl reductase. Bioorg. Med. Chem. Lett 2013, 23(7):2035-2043.
14. Crofton K.M., Paul K.B., Devito M.J., Hedge J.M. Short-term in vivo exposure to the water contaminant triclosan: evidence for disruption of thyroxine. Environ. Toxicol. Pharmacol 2007, 24(2):194-197.
15. Davis M.E., Chen Z.G., Shin D.M. Nanoparticle therapeutics. An emerging treatment modality for cancer. Nat. Rev. Drug Discov 2008, 7(9):771-782.
16. D'Angelo J.G., Bordón C., Posner G.H., Yolken R., Jones-Brando L. Artemisinin derivatives inhibit Toxoplasma gondii in vitro at multiple steps in the lytic cycle. J. Antimicrob. Chemother 2009, 63(1):146-150.
17. DeSalva S.J., Kong B.M., Lin Y.J. Triclosan: a safety profile. Am. J. Dent 1989, 2:185-196.
18. Djurković-Djaković O., Nikolić T., Robert-Gangneux F., Bobić B., Nikolić A. Synergistic effect of clindamycin and atovaquone in acute murine toxoplasmosis. Antimicrob. Agents Chemother 1999, 43(9):2240-2244.
19. Dubey J.P. The history of Toxoplasma gondii - the first 100 years. J. Eukaryot. Microbiol 2008, 55:467-475.
20. El Zawawy L.A. Effect of artesunate on Toxoplasma gondii: in vitro and in vivo studies. J. Egypt. Soc. Parasitol 2008, 38(1):185-201.
21. Elsheikha H.M. Congenital toxoplasmosis: priorities for further health promotion action. Public Health 2008, 122:335-353.
22. Ferguson D.J., Henriquez F.L., Kirisits M.J., Muench S.P., Prigge S.T., Rice D.W., et al. Maternal inheritance and stage-specific variation of the apicoplast in Toxoplasma gondii during development in the intermediate and definitive host. Eukaryot. Cell 2005, 4:814-826.
23. Fichera M.E., Roos D.S. A plastid organelle as a drug target in apicomplexan parasites. Nature 1997, 390(6658):407-409.
24. Gangneux J.P., Sulahian A., Garin Y.J., Farinotti R., Derouin F. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of Ambisome. Antimicrob. Agents Chemother 1996, 40(5):1214-1218.
25. Goodman C.D., McFadden G.I. Fatty acid biosynthesis as a drug target in apicomplexan parasites. Curr. Drug Targets 2007, 8(1):15-30.
26. Heath R.J., Rubin J.R., Holland D.R., Zhang E., Snow M.E., Rock C.O. Mechanism of triclosan inhibition of bacterial fatty acid synthesis. J. Biol. Chem 1999, 274(16):11110-11114.
27. Higgins J., Pinjon E., Oltean H.N., White T.C., Kelly S.L., Martel C.M., et al. Triclosan antagonizes fluconazole activity against Candida albicans. J. Dent. Res 2012, 91(1):65-70.
28. Jackowski S., Murphy C.M., Cronan J.B., Rock C.O. Acetoacetyl-acyl carrier protein synthase. A target for the antibiotic thiolactomycin. J. Biol. Chem 1989, 264:7624-7629.
29. Kasper L.H. Toxoplasma infection. Harrison's Principles of Internal Medicine 2001, vol. 1:1222-1227. McGraw-Hill, New York. fifteen ed.
30. Kirby C., Gregoriadis G. Dehydration-rehydration vesicles: a simple method for high yield drug entrapment in liposomes. Biotechnology 1984, 2:979-984.
31. Lu J.Z., Muench S.P., Allary M., Campbell S., Roberts C.W., Mui E., et al. Type I and type II fatty acid biosynthesis in Eimeria tenella: enoyl reductase activity and structure. Parasitology 2007, 134(14):1949-1962.
32. Luft B.J., Remington J.S. Toxoplasmic encephalitis in AIDS (AIDS commentary). Clin. Infect. Dis 1992, 15:211-222.
33. Maestrelli F., Mura P., Alonso M.J. Formulation and characterization of triclosan sub-micron emulsions and nanocapsules. J. Microencapsul 2004, 21:857-864.
34. Martins-Duarte E.S., Jones S.M., Gilbert I.H., Atella G.C., de Souza W., Vommaro R.C. Thiolactomycin analogues as potential anti-Toxoplasma gondii agents. Parasitol. Int 2009, 58(4):411-415.
35. McFadden G.I., Roos D.S. Apicomplexan plastids as drug targets. Trends Microbiol 1999, 7(8):328-333.
36. McLeod R., Muench S., Rafferty J., Kyle D., Mui E., Kirisits M., et al. Triclosan inhibits the growth of Plasmodium falciparum and Toxoplasma gondii by inhibition of apicomplexan Fab I. Int. J. Parasitol 2001, 31:109-113.
37. Mohanraj V.J., Chen Y. Nanoparticles - a review. Trop. J. Pharm. Res 2006, 5(1):561-573.
38. Mourão S.C., Costa P.I., Salgado H.R., Gremião M.P. Improvement of antischistosomal activity of praziquantel by incorporation into phosphatidylcholine-containing liposomes. Int. J. Pharm 2005, 295(1-2):157-162.
39. Muench S.P., Stec J., Zhou Y., Afanador G.A., McPhillie M.J., Hickman M.R., et al. Development of a triclosan scaffold which allows for adaptations on both the A- and B-ring for transport peptides. Bioorg. Med. Chem. Lett 2013, 23(12):3551-3555.
40. Mui E.J., Schiehser G.A., Milhous W.K., Hsu H., Roberts C.W., Kirisits M., et al. Novel triazine JPC-2067-B inhibits Toxoplasma gondii in vitro and in vivo. PloS Negl. Trop. Dis 2008, 2(3):190.
41. Paul K.B., Hedge J.M., DeVito M.J., Crofton K.M. Short-term exposure to triclosan decreases thyroxine in vivo via upregulation of hepatic catabolism in Young Long-Evans rats. Toxicol. Sci 2010, 113(2):367-379.
42. Paul K.S., Bacchi C.J., Englund P.T. Multiple triclosan targets in Trypanosoma brucei. Eukaryot. Cell 2004, 3(4):855-861.
43. Penido M.L.O., Nelson D.L., Vieira L.Q., Coelho P.M.Z. Schistosomal activity of alkyl aminooctane thiosulfuric acids. Mem. Inst. Oswaldo Cruz 1994, 89(4):595-602.
44. Pinkin F.P. Medical Statistics Made Easy 1984, Churchill Livingstone, Edinburgh, London, Melbourne, New York.
45. Puri A., Loomis K., Smith B., Yavlovich A., Heldman E., Blumenthal R., et al. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit. Rev. Ther. Drug Carrier Syst 2009, 26(6):523-580.
46. Romand S., Pudney M., Derouin F. In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii. Antimicrob. Agents Chemother 1993, 37(11):2371-2378.
47. Romand S., Della Bruna C., Farinotti R., Derouin F. In vitro and in vivo effects of rifabutin alone or combined with atovaquone against Toxoplasma gondii. Antimicrob. Agents Chemother 1996, 40(9):2015-2020.
48. Sakhrani N.M., Padh H. Organelle targeting: third level of drug targeting. Drug. Des. Devel. Ther 2013, 7:585-599.
49. Samuel B.U., Hearn B., Mack D., Wender P., Rothbard J., Kirisits M.J., et al. Delivery of antimicrobials into parasites. Proc. Natl. Acad. Sci. U.S.A. 2003, 100(24):14281-14286.
50. Sharma S., Ramya T.N.C., Surolia A., Surolia N. Triclosan as a systemic antibacterial agent in a mouse model of acute bacterial challenge. Antimicrob. Agents Chemother 2003, 47(12):3859-3866.
51. Singh A.P., Surolia N., Surolia A. Triclosan inhibit the growth of the late liver-stage of Plasmodium. IUBMB Life 2009, 61(9):923-928.
52. Sonda S., Sala G., Ghidoni R., Hemphill A., Pieters J. Inhibitory effect of aureobasidin A on Toxoplasma gondii. Antimicrob. Agents Chemother 2005, 49(5):1794-1801.
53. Stec J., Fomovska A., Afanador G.A., Muench S.P., Zhou Y., Lai B.S., et al. Modification of triclosan scaffold in search of improved inhibitors for enoyl-acyl carrier protein (ACP) reductase in Toxoplasma gondii. ChemMedChem 2013, 8(7):1138-1160.
54. Surolia N., Surolia A. Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum. Nat. Med 2001, 7:167-173.
55. Tachibana H., Yoshihara E., Kaneda Y., Nakae T. Protection of Toxoplasma gondii-infected mice by stearylamine-bearing liposomes. J. Parasitol 1990, 76(3):352-355.
56. Tanabe K., Kimata I., Tabuse Y., Furusawa M., Takada S. Toxoplasma gondii: penetration into differentiating friend erythroleukemia cells. Exp. Parasitol 1978, 46:72-82.
57. Tanaka T., Maeda H., Matsuo T., Boldbattar D., Umemiya-Shirafuji R., et al. Parasiticidal activity of Haemaphysalis longicornis longicin P4 peptide against Toxoplasma gondii. Peptides 2012, 34(1):242-250.
58. Tipparaju S.K., Muench S.P., Mui E.J., Ruzheinikov S.N., Lu J.Z., et al. Identification and development of novel inhibitors of Toxoplasma gondii enoyl reductase. J. Med. Chem 2010, 53(17):6287-6300.
59. Tomova C., Humbel B.M., Geerts W.J., Entzeroth R., Holthuis J.C., Verkleij A.J. Membrane contact sites between apicoplast and ER in Toxoplasma gondii revealed by electron tomography. Traffic 2009, 10(10):1471-1480.
60. Uhumwangho M.U., Okor R.S. Current trends in the production and biomedical applications of liposomes: a review. J. Biomed. Sci 2005, 4:9-21.
61. Vandhana S., Deepa P.R., Aparna G., Jayanthi U., Krishnakumar S. Evaluation of suitable solvents for testing the anti-proliferative activity of triclosan - a hydrophobic drug in cell culture. Indian J. Biochem. Biophys 2010, 47(3):166-171.
62. Vaughan A.M., O'Neill M.T., Tarun A.S., Camargo N., Phuong T.M., Aly A.S. Type II fatty acid synthesis is essential only for malaria parasite late liver stage development. Cell. Microbiol 2009, 11(3):506-520.
63. Waller R.F., Keeling P.J., Donald R.G., Striepen B., Handman E., Lang-Unnasch N., et al. Nuclear-encoded proteins target to the plastid in Toxoplasma gondii and Plasmodium falciparum. Proc. Natl. Acad. Sci. U.S.A. 1998, 95(21):12352-12357.
64. Waller R.F., Ralph S.A., Reed M.B., Su V., Douglas J.D., Minnikin D.E., et al. A type II pathway for fatty acid biosynthesis presents drug targets in Plasmodium falciparum. Antimicrob. Agents Chemother 2003, 47(1):297-301.
65. Weissa L.M., Dubey J.P. Toxoplasmosis: a history of clinical observations. Int. J. Parasitol 2009, 39(8):895-901.
66. Yin W.D., Gao Q.C., Liu X.D., Tang H.W. In vivo effect of dihydroartemisinin and azithromycin on the ultrastructure of Toxoplasma gondii tachyzoites. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 2009, 27(4):325-327.
67. Zaro J.L. Lipid-Based Drug Carriers for Prodrugs to Enhance Drug Delivery. AAPS. J. 2014, Epub ahead of print.
68. Zeng Y., Dong H., Han H., Jiang L., Zhao Q., Zhu S.H., et al. The ultrastructural effects of sulfachloropyrazine on Toxoplasma gondii tachyzoites. Iran. J. Parasitol 2013, 8(1):73-77.
69. Zorrilla L.M., Gibson E.K., Jeffay S.C., Crofton K.M., Setzer W.R., Cooper R.L., et al. The effects of triclosan on puberty and thyroid hormones in male Wistar rats. Toxicol. Sci 2009, 107(1):56-64.